10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 1,472,802 | $346,565,038 | +17% | 1.86% |
| 2. | AQR Capital Management Cliff Asness | 813,356 | $191,390,679 | +61% | 0.24% |
| 3. | 110,000,000 | $117,307,300 | +10% | 2.22% | |
| 4. | OrbiMed Advisors Samuel Isaly | 415,600 | $97,794,836 | +67% | 2.01% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 378,649 | $89,099,896 | +497% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.87 | 297,501 | Large Shareholder | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | Officer | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | Director | 27,900 | 2016-10-13 | Filing | |
| $58.36 | 2,000 | Director | 4,000 | 2016-03-09 | Filing | |
| $69.75 | 205,030 | Large Shareholder | 10,256,633 | 2016-02-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $300.00 | 5,445 | Officer | 20,221 | 2025-03-24 | Filing | |
| $285.00 | 4,321 | Officer | 20,221 | 2025-03-21 | Filing | |
| $299.00 | 7,440 | Director | 136 | 2025-03-24 | Filing | |
| $242.93 | 71 | Officer | 13,501 | 2025-03-04 | Filing | |
| $241.68 | 324 | Officer | 13,572 | 2025-03-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,000 | $1,080,080 | 0.04% | |
| 2. | 2,653 | $716,363 | 0.1% | |
| 3. | 398,000 | $458,297 | 0.06% | |
| 4. | 115,000 | $132,423 | 0% | |
| 5. | 336 | $90,727 | 0.02% |
News See All
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript February 13, 2025Alnylam Pharmaceuticals, Inc. misses on earnings expectations.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript October 31, 2024Alnylam Pharmaceuticals, Inc. beats earnings expectations.
Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s Performance
Fidelity Investments, an investment management company, released its “Fidelity Growth Strategies Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Aggressive Growth Stocks to Buy According to Hedge Funds
If you're putting money in the stock market, it's more likely than not that growth is the thing that's on your mind.
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q2
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Second Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75.
Billionaire Hedge Funds
